EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial

Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, Do-Youn Oh, Andree Rorive, Hatem Soliman, Shunji Takahashi, Tanios Bekaii-Saab, Mark E Burkard, Ki Y Chung, Philip R Debruyne, Jenny R Fox und 19 weitere

Nature Medicine · 2025

DOI: 10.1038/s41591-024-03462-0 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Nature Medicine, 2025. Verfasst von Alicia F C Okines und 30 weiteren Autor:innen. Beteiligte Einrichtung: The Royal Marsden NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Oxazoles, Pyridines. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated. SGNTUC-019 is an open-label, phase 2 basket study evaluating tucatinib, a HER2-targeted tyrosine kinase inhibitor, in combination with trastuzumab in patients with HER2-altered solid tumors. The study included a cohort of 31 heavily pretreated female patients with HER2-mutated metastatic breast cancer who were also HER2 negative per local testing. Hormone receptor (HR)-positive patients also received fulvestrant. The overall response rate (primary endpoint) was 41.9% (90% confidence interval (CI): 26.9-58.2). Secondary endpoints of duration of response and progression-free survival were 12.6 months (90% CI: 4.7 to not estimable) and 9.5 months (90% CI: 5.4-13.8), respectively. No new safety signals were detected. Responses were observed across various HER2 mutations, including mutations in the tyrosine kinase and extracellular domains. The chemotherapy-free regimen of tucatinib and trastuzumab showed clinically meaningful antitumor activity with durable responses and favorable tolerability in heavily pretreated patients with HER2 mutations. These data support further investigation of HER2-targeted therapies in this patient population. ClinicalTrials.gov registration: NCT04579380 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsOxazolesPyridinesQuinazolinesErb-b2 Receptor Tyrosine KinasesTrastuzumabAdultAgedFemaleHumansMiddle AgedMutationNeoplasm Metastasis

Substanzen

OxazolesPyridinesQuinazolinesErb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humantucatinib

Autor:innen und Institutionen

  • The Royal Marsden NHS Foundation Trust, London, UK.
  • Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
  • University of Milano, Milan, Italy.
  • Aichi Cancer Center Hospital, Nagoya, Japan.
  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea.
  • CHU Sart Tilman Liège, University of Liège, Liège, Belgium.

Förderung

  • NCI NIH HHS
  • Pfizer

Zitieren

APA

Okines, A. F. C., Curigliano, G., Mizuno, N., Oh, D. Y., Rorive, A., Soliman, H., Takahashi, S., Bekaii-Saab, T., Burkard, M. E., Chung, K. Y., Debruyne, P. R., Fox, J. R., Gambardella, V., Gil-Martin, M., Hamilton, E. P., Monk, B. J., Nakamura, Y., Nguyen, D., O'Malley, D. M., …, & Pohlmann, P. R. (2025). Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03462-0

Vancouver

Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, et al. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nature Medicine. 2025. doi:10.1038/s41591-024-03462-0

BibTeX
@article{Okines2025,
  author = {Okines, Alicia F C and Curigliano, Giuseppe and Mizuno, Nobumasa and Oh, Do-Youn and Rorive, Andree and Soliman, Hatem and Takahashi, Shunji and Bekaii-Saab, Tanios and Burkard, Mark E and Chung, Ki Y and Debruyne, Philip R and Fox, Jenny R and Gambardella, Valentina and Gil-Martin, Marta and Hamilton, Erika P and Monk, Bradley J and Nakamura, Yoshiaki and Nguyen, Danny and O'Malley, David M and Olawaiye, Alexander B and Pothuri, Bhavana and Reck, Martin and Sudo, Kazuki and Sunakawa, Yu and Van Marcke, Cedric and Yu, Evan Y and Ramos, Jorge and Tan, Sherry and Bieda, Mark and Stinchcombe, Thomas E and Pohlmann, Paula R},
  title = {Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial},
  journal = {Nature Medicine},
  year = {2025},
  doi = {10.1038/s41591-024-03462-0}
}
Kostenlos starten →